

1. General Information

Cohort ID	5001_15
Title (Study Name)	BioPersMed
Principal investigator	Prof.in Barbara Obermayer-Pietsch, Prof. Thomas Pieber, Prof. Andreas Zirlík, Prof. Rudolf Stauber
Contact information	pm-biobank@medunigraz.at
Funding agency	FFG: COMET

2. Description

This cohort comprises a huge number of samples and data collected since 2010 and is still ongoing. The aim is to detect biomarkers of patients at risk for cardiovascular and metabolic diseases. The BioPersMed cohort includes the areas: endocrinology & metabolism and cardiology. In the focus of this cohort: e.g. diabetes, fatty liver disease, osteoporosis, cardiovascular diseases. The biobank specimen comprise plasma, serum, buffy coat and urine stored at -80°C with 24/7 temperature surveillance, as well as the according clinical data including a large set of metabolic, cardiovascular, hormonal and general lab and imaging parameters.

3. Details

ICD 10/O codes / Healthy	E11; E66; M80; M81; I20-I25; R55; I38; I70; I99; I48, Healthy	
Key words	biomarker, metabolism, cardiology, diabetes, osteoporosis, fatty liver disease, cardiovascular diseases, endocrinology	
Collection / Cohort size 11/2021	311.839 aliquots from 1.006 patients	
Informed Consent (IC)	<input checked="" type="checkbox"/> Broad Biobank IC	
	<input checked="" type="checkbox"/> Specific Study IC	
Status	<input checked="" type="checkbox"/> In progress / compl. date: open	
	<input type="checkbox"/> Completed	
Inclusion criteria	Age distribution	>35
	Sex distribution (f:m)	50:50
	Others	-----
Earliest access	As of now	
Quality-standards	<input checked="" type="checkbox"/> ISO 9001:2015 (SOPs)	
Associated publications / references	<p><u>Cohort profile: 'Biomarkers of Personalised Medicine' (BioPersMed): a single-centre prospective observational cohort study in Graz/Austria to evaluate novel biomarkers in cardiovascular and metabolic diseases.</u> Haudum CW, Kolesnik E, Colantonio C, Mursic I, Url-Michitsch M, Tomaschitz A, Glantschnig T, Hutz B, Lind A, Schweighofer N, Reiter C, Ablasser K, Wallner M, Tripolt NJ, Pieske-Kraigher E, Madl T, Springer A, Seidel G, Wedrich A, Zirlík A, Krahn T, Stauber R, Pieske B, Pieber TR, Verheyen N, Obermayer-Pietsch B, Schmidt A. https://pubmed.ncbi.nlm.nih.gov/35393327/</p>	

4. Material available (aliquot size) and storage conditions

Material	<input checked="" type="checkbox"/> Serum (1000 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> EDTA plasma (1000 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> EDTA Buffy coat (300 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> Li-Hep plasma (400 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> Na-Citrate plasma (400 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> Urine (1000 µl)	<input checked="" type="checkbox"/> -80°C

Dokument erstellt (tt/mm/yyyy):
22/04/2021

Letzte inhaltliche Aktualisierung (tt/mm/yyyy):
20/05/2022